Sparsentan

(Filspari®)

Sparsentan

Drug updated on 10/21/2024

Dosage FormTablet (oral; 200 mg, 400 mg)
Drug ClassEndothelin and angiotensin II receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Sparsentan vs. Irbesartan: The effectiveness of sparsentan in reducing proteinuria compared to irbesartan remains uncertain, as reported in the included study.
  • Cyclosporin Effectiveness: Cyclosporin, with or without prednisone, may increase the likelihood of complete remission (RR 2.31, 95% CI 1.13 to 4.73) and complete or partial remission (RR 1.64, 95% CI 1.10 to 2.44) in patients with steroid-resistant FSGS. However, cyclosporin may not significantly increase the likelihood of partial remission alone (RR 1.36, 95% CI 0.78 to 2.39).
  • Mycophenolate Mofetil (MMF): MMF compared with prednisone may not significantly impact the likelihood of achieving complete remission (RR 1.05, 95% CI 0.58 to 1.88) or partial remission in steroid-resistant FSGS.
  • Cyclosporin Safety: Cyclosporin may have little or no effect on chronic kidney disease, kidney failure, hypertension, or infection outcomes when compared to other treatments. The safety of cyclosporin regarding these specific adverse outcomes remains uncertain.
  • Mycophenolate Mofetil (MMF) Safety: MMF, compared to prednisone, may not significantly affect the likelihood of infection, as there was little to no difference observed between the two treatments.
  • The systematic review included participants with steroid-resistant FSGS, but no additional information on other specific population types or subgroups (e.g., age, gender) was provided. There are no significant subgroup findings beyond those related to steroid-resistant FSGS.

Product Monograph / Prescribing Information

Document TitleYearSource
Filspari (sparsentan) Prescribing Information.2024Travere Therapeutics, Inc., San Diego, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Interventions for focal segmental glomerulosclerosis in adults2022The Cochrane Database of Systematic Reviews

Clinical Practice Guidelines

Document TitleYearSource
Practical considerations for the use of sparsentan in the treatment of patients with IgAN in clinical practice.2023International Journal of Nephrology and Renovascular Disease